Cognition Therapeutics Inc (CGTX) shareholders
Close on Nov 17, 2026Market cap $59.90MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Aaron G.L. Fletcher Joint filing with Bios Capital Management, LP (6.80%), Bios Advisors Gp, LLC (6.80%) and 3 more | 6,059,555 | 6.90% | 13D (active) amendment | Sep 19, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CGTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BIOS Capital Management, LP | 6,000,000 | 6.31% | $6.90M | – | 16.56% |
| DAVENPORT & Co LLC | 4,259,511 | 4.48% | $4.90M | +1,366,703 | 0.02% |
| Vanguard Capital Management LLC | 3,438,775 | 3.62% | $3.95M | +436,988 | 0.00% |
| BlackRock, Inc. | 1,261,993 | 1.33% | $1.45M | +293,631 | 0.00% |
| Chescapmanager LLC | 997,029 | 1.05% | $1.15M | – | 0.10% |
| Geode Capital Management, LLC | 910,006 | 0.96% | $1.05M | −10,202 | 0.00% |
| Renaissance Technologies LLC | 693,288 | 0.73% | $797.28K | −423,848 | 0.00% |
| Hilton Capital Management, LLC | 548,950 | 0.58% | $631.29K | – | 0.04% |
| Vanguard Fiduciary Trust Co | 508,220 | 0.53% | $584.45K | +44,536 | 0.00% |
| CM Management, LLC | 450,000 | 0.47% | $517.50K | +50,000 | 0.34% |
| Dauntless Investment Group, LLC | 371,701 | 0.39% | $427.46K | −59,299 | 0.34% |
| Sigma Planning Corp | 362,265 | 0.38% | $416.61K | +24,500 | 0.01% |
| State Street Corp | 348,983 | 0.37% | $401.33K | +34,500 | 0.00% |
| Tocqueville Asset Management L.P. | 320,500 | 0.34% | $368.58K | +125,500 | 0.00% |
| UBS Group AG | 218,536 | 0.23% | $251.32K | +141,663 | 0.00% |
| American Financial Group Inc | 205,000 | 0.22% | $235.75K | – | 0.08% |
| Northern Trust Corp | 178,202 | 0.19% | $204.93K | +9,516 | 0.00% |
| Voss Capital, LLC | 175,000 | 0.18% | $201.25K | −25,000 | 0.01% |
| Texas Capital Bank Wealth Management Services Inc | 143,296 | 0.15% | $164.79K | +20,000 | 0.01% |
| Charles Schwab Investment Management Inc | 84,940 | 0.09% | $97.68K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 66 | 23M | 23.8% | 4 / 23 | 10 / 13 | 3M | 1M |
| Q1 2026 | 75 | 21M | 22.5% | 13 / 18 | 14 / 14 | 5M | 1M |
| Q4 2025 | 78 | 21M | 22.6% | 17 / 17 | 16 / 8 | 3M | 3M |
| Q3 2025 | 69 | 21M | 22.4% | 31 / 23 | 4 / 8 | 12M | 1M |
| Q2 2025 | 48 | 11M | 11.8% | 7 / 10 | 7 / 10 | 1M | 1M |
| Q1 2025 | 51 | 12M | 12.2% | 11 / 10 | 12 / 4 | 1M | 1M |
| Q4 2024 | 45 | 11M | 11.7% | 8 / 12 | 9 / 2 | 7M | 0M |
| Q3 2024 | 40 | 4M | 4.5% | 10 / 6 | 5 / 14 | 1M | 2M |
| Q2 2024 | 46 | 5M | 5.6% | 5 / 14 | 8 / 6 | 1M | 2M |
| Q1 2024 | 47 | 7M | 7.5% | 15 / 9 | 10 / 5 | 3M | 3M |
| Q4 2023 | 37 | 7M | 7.5% | 7 / 10 | 2 / 4 | 3M | 0M |
| Q3 2023 | 36 | 7M | 7.6% | 2 / 5 | 7 / 1 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
15 funds held CGTX in Q2 2026, 80% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CGTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,444,295 | 2.57% | $2.81M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 871,598 | 0.92% | $1.00M | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 416,139 | 0.44% | $491.04K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 275,235 | 0.29% | $316.52K | 0.02% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 143,771 | 0.15% | $169.65K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 118,702 | 0.12% | $140.07K | 0.00% | May 31, 2026 |
| Schwab Total Stock Market Index Fund | 84,940 | 0.09% | $75.56K | 0.00% | Jul 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 51,054 | 0.05% | $60.24K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 38,785 | 0.04% | $44.60K | 0.00% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 31,797 | 0.03% | $36.57K | 0.00% | Jun 30, 2026 |
| Gabelli Global Mini Mites Fund | 30,000 | 0.03% | $34.50K | 0.13% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 18,396 | 0.02% | $21.16K | 0.01% | Jun 30, 2026 |
| iShares Neuroscience and Healthcare ETF | 4,543 | 0.00% | $4.04K | 0.07% | Jul 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -27,700 | -0.03% | -$31.86K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Lisa Ricciardi | CEO & President, Director | 1,754,702 | 1.85% | Apr 20, 2026 |
| John Brendan Doyle | Chief Financial Officer | 618,942 | 0.65% | May 4, 2026 |
| Anthony Caggiano | Chief Medical Officer | 874,906 | 0.92% | Apr 20, 2026 |
| Aaron G.L. Fletcher | Director, 10% owner | 6,056,229 | 6.37% | Jun 22, 2026 |
| Bios Equity Partners, LP | Director, 10% owner | – | – | Jun 22, 2026 |
| Ellen B. Richstone | Director | 83,500 | 0.09% | Jun 22, 2026 |
| Brett P. Monia | Director | 73,500 | 0.08% | Jun 22, 2026 |
| BIOS Fund I, LP | Director, 10% owner | 5,505,905 | 5.79% | Jun 22, 2026 |
| Bios Equity Partners II, LP | Director, 10% owner | 6,014,500 | 6.32% | Jun 22, 2026 |
| BIOS Capital Management, LP | Director, 10% owner | – | – | Jun 22, 2026 |
| BIOS Fund II, LP | Director, 10% owner | – | – | Jun 22, 2026 |
| BIOS Fund I QP, LP | Director, 10% owner | 5,499,905 | 5.78% | Jun 22, 2026 |
| Jack A. Khattar | Director | 73,500 | 0.08% | Jun 22, 2026 |
| BIOS Advisors GP, LLC | Director, 10% owner | 6,048,500 | 6.36% | Jun 22, 2026 |
| BIOS Fund II QP, LP | Director, 10% owner | – | – | Jun 22, 2026 |
| Peggy Wallace | Director | 111,461 | 0.12% | Jun 22, 2026 |
| BIOS Memory SPV I, LP | Director, 10% owner | 6,081,229 | 6.39% | Jun 22, 2026 |
| BP Directors, LP | Director, 10% owner | – | – | Jun 20, 2025 |
| BIOS Equity Partners III, LP | Director, 10% owner | – | – | Jun 20, 2025 |
| BIOS Fund III, LP | Director, 10% owner | 6,048,500 | 6.36% | Jun 20, 2025 |
| BIOS Fund III QP, LP | Director, 10% owner | 5,499,905 | 5.78% | Jun 20, 2025 |
| BIOS Fund III NT, LP | Director, 10% owner | 5,483,841 | 5.77% | Jun 20, 2025 |
| BIOS Memory SPV II, LP | Director, 10% owner | 5,505,905 | 5.79% | Jun 20, 2025 |
| Leslie W. Kreis | Director, 10% owner | 6,014,500 | 6.32% | Jun 20, 2025 |
| Cavu Advisors, LLC | Director, 10% owner | – | – | Jun 20, 2025 |
| Cavu Management, LP | Director, 10% owner | 5,412,841 | 5.69% | Jun 20, 2025 |
| BIOS Fund II NT, LP | Director, 10% owner | – | – | Jun 20, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Ellen B. Richstone Director | Jun 17, 2026 | Award | +25,000 | – | – | 83,500 |
| Jack A. Khattar Director | Jun 17, 2026 | Award | +25,000 | – | – | 73,500 |
| Peggy Wallace Director | Jun 17, 2026 | Award | +25,000 | – | – | 111,461 |
| BIOS Memory SPV I, LP Director, 10% owner | Jun 17, 2026 | Award | +25,000 | – | – | 81,229 |
| Brett P. Monia Director | Jun 17, 2026 | Award | +25,000 | – | – | 73,500 |
| John Brendan Doyle Chief Financial Officer | May 1, 2026 | Tax withholding | −8,567 | $1.28 | $10.97K | 618,942 |
| John Brendan Doyle Chief Financial Officer | Apr 16, 2026 | Buy | +10,000 | $1.13 | $11.30K | 627,509 |
| Lisa Ricciardi CEO & President, Director | Apr 16, 2026 | Buy | +9,175 | $1.10 | $10.09K | 1,715,851 |
| Anthony Caggiano Chief Medical Officer | Apr 16, 2026 | Buy | +10,000 | $1.11 | $11.10K | 874,906 |
| Lisa Ricciardi CEO & President, Director | Feb 15, 2026 | Tax withholding | −5,850 | $1.12 | $6.55K | 1,706,676 |
| Anthony Caggiano Chief Medical Officer | Feb 15, 2026 | Tax withholding | −4,680 | $1.12 | $5.24K | 864,906 |
| John Brendan Doyle Chief Financial Officer | Feb 15, 2026 | Tax withholding | −1,560 | $1.12 | $1.75K | 617,509 |
| Anthony Caggiano Chief Medical Officer | Feb 4, 2026 | Tax withholding | −26,919 | $1.03 | $27.73K | 869,586 |
| John Brendan Doyle Chief Financial Officer | Feb 4, 2026 | Tax withholding | −26,921 | $1.03 | $27.73K | 619,069 |
| Lisa Ricciardi CEO & President, Director | Feb 4, 2026 | Tax withholding | −51,704 | $1.03 | $53.26K | 1,712,526 |
| Anthony Caggiano Chief Medical Officer | Feb 3, 2026 | Award | +400,000 | – | – | 907,993 |
| Anthony Caggiano Chief Medical Officer | Feb 3, 2026 | Tax withholding | −11,488 | $1.12 | $12.87K | 896,505 |
| John Brendan Doyle Chief Financial Officer | Feb 3, 2026 | Award | +200,000 | – | – | 645,990 |
| Lisa Ricciardi CEO & President, Director | Feb 3, 2026 | Award | +800,000 | – | – | 1,790,266 |
| Lisa Ricciardi CEO & President, Director | Feb 3, 2026 | Tax withholding | −26,036 | $1.12 | $29.16K | 1,764,230 |
| John Brendan Doyle Chief Financial Officer | Dec 18, 2025 | Award | +30,000 | – | – | 455,350 |
| John Brendan Doyle Chief Financial Officer | Dec 18, 2025 | Tax withholding | −9,360 | $1.50 | $14.04K | 445,990 |
| Anthony Caggiano Chief Medical Officer | Dec 18, 2025 | Award | +65,000 | – | – | 528,273 |
| Anthony Caggiano Chief Medical Officer | Dec 18, 2025 | Tax withholding | −20,280 | $1.50 | $30.42K | 507,993 |
| Lisa Ricciardi CEO & President, Director | Dec 18, 2025 | Award | +75,000 | – | – | 1,013,666 |
| Lisa Ricciardi CEO & President, Director | Dec 18, 2025 | Tax withholding | −23,400 | $1.50 | $35.10K | 990,266 |
| Aaron G.L. Fletcher Director, 10% owner | Sep 19, 2025 | Option exercise | +7,729 | $0.84 | $6.49K | 56,229 |
| Lisa Ricciardi CEO & President, Director | Jul 29, 2025 | Tax withholding | −23,400 | $0.67 | $15.68K | 938,666 |
| Lisa Ricciardi CEO & President, Director | Jul 29, 2025 | Award | +75,000 | – | – | 962,066 |
| Anthony Caggiano Chief Medical Officer | Jul 29, 2025 | Award | +65,000 | – | – | 483,554 |
| Anthony Caggiano Chief Medical Officer | Jul 29, 2025 | Tax withholding | −20,281 | $0.67 | $13.59K | 463,273 |
| John Brendan Doyle Chief Financial Officer | Jul 29, 2025 | Tax withholding | −9,360 | $0.67 | $6.27K | 425,350 |
| John Brendan Doyle Chief Financial Officer | Jul 29, 2025 | Award | +30,000 | – | – | 434,710 |
| Brett P. Monia Director | Jun 18, 2025 | Award | +34,000 | – | – | 48,500 |
| Jack A. Khattar Director | Jun 18, 2025 | Award | +34,000 | – | – | 48,500 |
| Peggy Wallace Director | Jun 18, 2025 | Award | +34,000 | – | – | 86,461 |
| Ellen B. Richstone Director | Jun 18, 2025 | Award | +34,000 | – | – | 58,500 |
| BIOS Advisors GP, LLC Director, 10% owner | Jun 18, 2025 | Award | +34,000 | – | – | 48,500 |
| BIOS Fund III, LP Director, 10% owner | Jun 18, 2025 | Award | +34,000 | – | – | 48,500 |
| John Brendan Doyle Chief Financial Officer | May 1, 2025 | Tax withholding | −9,692 | $0.45 | $4.36K | 404,710 |
| Lisa Ricciardi CEO & President, Director | Feb 15, 2025 | Tax withholding | −6,619 | $0.59 | $3.91K | 887,066 |
| Anthony Caggiano Chief Medical Officer | Feb 15, 2025 | Tax withholding | −5,296 | $0.59 | $3.12K | 418,554 |
| John Brendan Doyle Chief Financial Officer | Feb 15, 2025 | Tax withholding | −1,723 | $0.59 | $1.02K | 414,402 |
| John Brendan Doyle Chief Financial Officer | Feb 4, 2025 | Award | +295,000 | – | – | 416,125 |
| Anthony Caggiano Chief Medical Officer | Feb 4, 2025 | Award | +295,000 | – | – | 423,850 |
| Lisa Ricciardi CEO & President, Director | Feb 4, 2025 | Award | +631,300 | – | – | 893,685 |
| Anthony Caggiano Chief Medical Officer | Feb 3, 2025 | Tax withholding | −12,779 | $0.67 | $8.56K | 128,850 |
| Lisa Ricciardi CEO & President, Director | Feb 3, 2025 | Tax withholding | −28,960 | $0.67 | $19.40K | 262,385 |
| Lisa Ricciardi CEO & President, Director | Jan 31, 2025 | Buy | +38,851 | $0.77 | $29.92K | 38,851 |
| Ellen B. Richstone Director | Jun 7, 2024 | Award | +8,500 | – | – | 24,500 |
| Brett P. Monia Director | Jun 7, 2024 | Award | +8,500 | – | – | 14,500 |
| Jack A. Khattar Director | Jun 7, 2024 | Award | +8,500 | – | – | 14,500 |
| Peggy Wallace Director | Jun 7, 2024 | Award | +8,500 | – | – | 52,461 |
| Bios Equity Partners II, LP Director, 10% owner | Jun 7, 2024 | Award | +8,500 | – | – | 14,500 |
| Leslie W. Kreis Director, 10% owner | Jun 7, 2024 | Award | +8,500 | – | – | 14,500 |
| John Brendan Doyle Chief Financial Officer | May 1, 2024 | Tax withholding | −8,699 | $1.95 | $16.96K | 121,125 |
| Lisa Ricciardi CEO & President, Director | Mar 14, 2024 | Buy | +5,700 | $1.75 | $9.98K | 291,345 |
| Lisa Ricciardi CEO & President, Director | Feb 15, 2024 | Award | +75,000 | – | – | 285,645 |
| Anthony Caggiano Chief Medical Officer | Feb 15, 2024 | Award | +60,000 | – | – | 141,629 |
| John Brendan Doyle Chief Financial Officer | Feb 15, 2024 | Award | +20,000 | – | – | 129,824 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Cognition Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 16,196 shares on Sep 18, 2026 over the last 90 days.
See a number that looks wrong?